Find your compound, get the exact amount of water to add and the exact number of units to draw, then mix it and store it right. Built in the order you actually work in, not the order a textbook would list. One page, one email, no login.
For educational and research purposes only. This is not medical advice and is not human-use guidance. Dose figures are research reference ranges, not instructions. Consult a qualified professional before acting on anything here.
Free, no payment required
Below this point is the searchable compound reference, the dosing calculator, the gear list, the slow drip method, and the full storage section. Enter your email to unlock all of it. One step, no account needed.
No spam. Used only for research guide access and occasional protocol updates from Project Theo.
The full tool covers more compounds than the tables below and does the whole job in one place: concentration, units to draw, doses per vial, and full cycle planning. Skip the guide and go straight to your numbers.
Start here
Search your compound and read the row. It gives you the reference water amount, the reference dose and how often, the units to draw on a U-100 insulin syringe, how many doses a vial holds, and the route. If you already know what you are holding, this row is the whole answer. If your vial size or water amount is different, use the calculator in the next section.
Filters the planning sheet and the route tables below at the same time.
| Peptide | Eff. dose ref. | Frequency | BAC vol | Vol / dose | Days / vial | Min cycle | Max cycle |
|---|---|---|---|---|---|---|---|
| AOD-9604 (10mg) | 350 mcg | 1x/day | 2.0mL | 0.07mL / 7u | 28 | 28d | 56d |
| BPC-157 (5mg) | 250 mcg | 1x/day | 1.5mL | 0.075mL / 7.5u | 20 | 14d | 56d |
| CJC-1295 No DAC (5mg) | 100–200 mcg | 2x/day | 2.0mL | 0.04mL / 4u | 25 | 28d | 56d |
| CJC-1295 No DAC (10mg) | 100–200 mcg | 2x/day | 2.0mL | 0.02mL / 2u | 50 | 100d | 100d |
| DSIP (5mg) | 300 mcg | 1x/night | 1.5mL | 0.09mL / 9u | 16.7 | 14d | 42d |
| Epithalon (10mg) | 5–10 mg | 1x/day | 2.0mL | 1.0mL / 100u | 2–4 | 10d | 20d |
| GHK-Cu (50mg) | 2 mg | 1x/day | 5.0mL | 0.20mL / 20u | 25 | 28d | 56d |
| GHRP-6 (10mg) | 100 mcg | 2x/day | 2.0mL | 0.02mL / 2u | 50 | 28d | 56d |
| Gonadorelin (2mg) | 100 mcg | 2x/week | 2.0mL | 0.10mL / 10u | 20 | 8w | 16w |
| HCG (5,000 IU) | 500 IU | 2x/week | 5.0mL | 0.50mL / 50u | 35 | 28d | 56d |
| Ipamorelin (5mg) | 200 mcg | 2x/day | 2.0mL | 0.08mL / 8u | 12.5 | 28d | 56d |
| Ipamorelin (10mg) | 200 mcg | 2x/day | 2.0mL | 0.04mL / 4u | 25 | 28d | 56d |
| KPV (10mg) | 250–500 mcg | 1x/day | 2.0mL | 0.05mL / 5u | 20–40 | 28d | 56d |
| LL-37 (5mg) | 100–200 mcg | 1x/day | 1.5mL | 0.03mL / 3u | 25–50 | 14d | 28d |
| MOTS-c (10mg) | 500 mcg | 1x/day | 2.0mL | 0.10mL / 10u | 20 | 28d | 56d |
| NAD+ (500mg) | 50 mg | 2x/week | 5.0mL | 0.50mL / 50u | 35 | 28d | 56d |
| Oxytocin (2mg) | 0.15 mg | 1x/day | 2.0mL | 0.15mL / 15u | 13.3 | 28d | 56d |
| PT-141 (10mg) | 1.25 mg | 2x/week | 2.0mL | 0.25mL / 25u | 28 | 14d | 56d |
| Retatrutide (5mg) | 1 mg | 2x/week | 1.0mL | 0.20mL / 20u | 17.5 | 28d | 84d |
| Retatrutide (10mg) | 1 mg | 2x/week | 2.0mL | 0.20mL / 20u | 35 | 28d | 84d |
| Retatrutide (15mg) | 1 mg | 2x/week | 3.0mL | 0.20mL / 20u | 52.5 | 28d | 84d |
| Retatrutide (20mg) | 1 mg | 2x/week | 3.0mL | 0.15mL / 15u | 70 | 28d | 84d |
| Semax (10mg) | 300 mcg | 2x/day | 1.0mL | 0.03mL / 3u | 16 | 14d | 28d |
| Selank (10mg) | 300 mcg | 2x/day | 1.0mL | 0.03mL / 3u | 16 | 14d | 28d |
| SS-31 (5mg) | 1–2 mg | 1x/day | 2.0mL | 0.40mL / 40u | 5–10 | 14d | 28d |
| TB-500 (5mg) | 2 mg | 1x/week | 2.0mL | 0.80mL / 80u | 6.25 | 28d | 56d |
| Tesamorelin (5mg) | 1 mg | 1x/day | 2.5mL | 0.50mL / 50u | 5 | 28d | 56d |
| Tesamorelin (10mg) | 1 mg | 1x/day | 2.5mL | 0.25mL / 25u | 10 | 28d | 56d |
| Thymosin Alpha-1 (5mg) | 900 mcg | 2x/week | 2.0mL | 0.36mL / 36u | 13.9 | 28d | 84d |
| Wolverine Blend 10mg | 250 mcg ea. | 1x/day | 2.0mL | 0.10mL / 10u | 20 | 28d | 56d |
| Wolverine Blend 20mg | 250 mcg ea. | 1x/day | 2.0mL | 0.05mL / 5u | 40 | 28d | 56d |
No compound matches that search in this table.
Values are general research reference ranges only, not dosing instructions for human use. Ranges show the low end in the Vol per dose column. Epithalon is dosed in milligrams, so its draw is a large volume that empties a vial in a few days. Confirm your intended dose before relying on any figure.
How to read your syringe. On a standard U-100 insulin syringe, 100 units equals 1mL. Units and milliliters are not two systems. Units are simply the marks on that 1mL scale. Once you know the concentration, the unit line is just the liquid volume you are pulling. The syringe does not know the compound dose, it only knows the liquid amount.
Same compounds, grouped by how each one is most commonly administered in research contexts. Some appear in more than one group because research has studied them through several routes with different effects at each site. Every range here is general research reference data, not instructions for human use.
Usually drawn from a reconstituted vial with a U-100 insulin syringe and injected into subcutaneous (under-skin) tissue, commonly the abdomen or thigh.
| Compound | Research dose range | Frequency | Primary mechanism (plain English) |
|---|---|---|---|
| AOD-9604 | 250–500 mcg | Daily / fasted | A fragment of the GH sequence studied for fat-mobilization logic rather than GH replacement. |
| BPC-157 | 250–500 mcg | 1–2x/day | Studied for gut-lining support and local tissue repair signaling, especially where inflammation or soft-tissue stress is part of the picture. |
| CJC-1295 (No DAC) | 100–300 mcg | 1–2x/day, fasted | A GHRH analog studied to support the body's own GH pulse rather than supplying outside growth hormone. |
| DSIP | 100–300 mcg | Nightly | Researched for sleep architecture support, especially when deep-sleep quality looks like the limiting variable. |
| Epithalon | 5–10 mg | Nightly / split | Studied for pineal and melatonin-related signaling, usually in longevity research rather than acute physique use. |
| GHK-Cu | 1–2 mg | Daily / several x/wk | A copper peptide studied for tissue quality, skin remodeling, and repair signaling rather than fat loss directly. |
| GHRP-6 | 100–300 mcg | 1–3x/day, fasted | A ghrelin receptor agonist studied to amplify GH release, but also known for a strong hunger signal. |
| Gonadorelin | 100–300 mcg | 2–3x/week | Studied for hypothalamic-pituitary-gonadal (hormone axis) signaling where suppression, flat mood, and low drive are part of the case. |
| HCG | 250–500 IU | 2–3x/week | Studied for testicular signaling support in hormone axis research. Not a peptide, but commonly grouped with peptide protocols. |
| Ipamorelin | 100–300 mcg | 1–2x/day, fasted | A ghrelin mimetic studied to amplify GH pulse signaling with less appetite drive than older GHRPs. |
| Kisspeptin-10 | 100–300 mcg | 2–3x/week | Studied for upstream reproductive hormone signaling and hypothalamic control rather than direct body composition. |
| KPV | 250–500 mcg | 1–2x/day | A short anti-inflammatory peptide studied where gut irritation and systemic inflammatory signaling overlap. Also oral. |
| LL-37 | 100–250 mcg | Daily / several x/wk | An antimicrobial peptide studied in immune and wound-related research, usually handled with more caution than standard repair peptides. |
| MOTS-c | 5–15 mg | 2–3x/week | A mitochondrial (cell energy) signaling peptide studied for energy handling and AMPK-related adaptation rather than appetite suppression. |
| NAD+ | 25–100 mg | 2–5x/week | A redox cofactor (cell fuel helper) studied for output capacity when fatigue is part of the bottleneck. |
| Oxytocin Acetate | 100–300 mcg | As scheduled | Studied for social bonding, stress regulation, and sometimes appetite-related signaling. Context matters heavily here. |
| PT-141 (Bremelanotide) | 0.5–2 mg | As needed | A melanocortin agonist studied mainly for arousal signaling, not as a body composition tool. Also intranasal. |
| Retatrutide | 1–8 mg | Weekly | A triple agonist studied for intake control plus output pressure through glucagon signaling, which changes how hunger and heat are read. |
| Semax | 300–900 mcg | Daily / split | A nootropic (cognition) peptide researched for cognitive signaling. Some setups study SubQ delivery alongside the more common intranasal route. |
| Selank | 250–500 mcg | Daily / split | An anxiolytic (anti-anxiety) peptide more often studied intranasally, with SubQ use appearing in some research contexts. |
| SS-31 (Elamipretide) | 5–20 mg | Daily | A mitochondrial peptide studied to stabilize inner-membrane function when energy inefficiency, not appetite, is the actual problem. |
| TB-500 | 2–5 mg | Weekly / split | A systemic repair peptide studied for cell migration and recovery signaling across soft tissue and connective tissue. |
| Tesamorelin | 1–2 mg | Daily | A GHRH analog studied for stronger, more measurable GH pathway pressure, often when visceral fat and lean-mass protection are central. |
| Thymosin Alpha-1 | 0.5–1.5 mg | 2–3x/week | An immune-signaling peptide studied when recovery, inflammation, and immune resilience overlap. |
| Wolverine Blend (BPC+TB-500) | Varies by blend | Daily + weekly | A combination used in repair research to pair local gut and tissue signaling with broader systemic recovery. |
No compound matches that search in this table.
Used most in nootropic, anxiolytic, and certain specialty signaling contexts where fast, non-injectable delivery is part of the research setup.
| Compound | Research dose range | Frequency | Primary mechanism |
|---|---|---|---|
| Semax | 300–900 mcg | Daily / split | Studied for BDNF-related cognitive signaling, especially where mental flatness and reduced focus sit inside a larger recovery problem. |
| Selank | 250–500 mcg | Daily / split | Studied for stress and anxiety regulation without the sedation profile many researchers try to avoid. |
| PT-141 (Bremelanotide) | 1–5 mg equiv. | Intermittent | An alternate route for melanocortin signaling research, same basic mechanism but a different onset profile. |
| Oxytocin | 100–300 mcg | Intermittent / daily | Studied for bonding, calmness, and stress-related signaling. Interpretation depends heavily on context and intent. |
| Cerebrolysin | Protocol dependent | Protocol dependent | Often discussed in neural recovery circles. Intranasal discussion exists but the evidence is uneven. Not a peptide in the narrow sense. |
| Dihexa | 5–20 mg | Daily | A research-stage cognitive compound discussed for synaptic and learning-related signaling. Still highly experimental with limited human data. |
| PE-22-28 | 400–1000 mcg | Daily | An experimental anxiolytic peptide discussed in nootropic communities with limited formal human data. |
| NA-1 (Nerinetide) | Protocol dependent | Acute / short block | Stroke and neuroprotection literature drives most discussion here. Not a casual peptide reference item. |
No compound matches that search in this table.
Included because many researchers group these with peptide workflows even when the compound itself is not technically a peptide.
| Compound | Research dose range | Frequency | Notes |
|---|---|---|---|
| BPC-157 (oral form) | 250–1000 mcg | 1–2x/day | The oral form is usually studied for GI-targeted support rather than the broader repair logic often assumed from injectable use. |
| KPV | 250–1000 mcg | 1–2x/day | Oral use is usually discussed when gut inflammation is the leading issue rather than systemic performance. Also SubQ. |
| Larazotide (AT-1001) | 0.25–1 mg | 1–3x/day | A tight-junction modulator (gut barrier) studied in gut research rather than physique applications. |
| MK-677 (Ibutamoren) | 10–25 mg | Daily | Not a peptide. An oral secretagogue studied for sustained GH and IGF-1 pathway stimulation through ghrelin receptor signaling. |
| SLU-PP-332 | 50–200 mcg (early discussion) | Daily, research stage | Research suggests ERR pathway activation may influence mitochondrial biogenesis and metabolic output. Human data remains extremely limited as of early 2026. |
No compound matches that search in this table.
Your mix
Pick your compound to autofill the reference vial size, water, and dose, then adjust anything that does not match what you are holding. Or type all three yourself. It returns the concentration and the units to draw on a U-100 syringe. It converts the numbers you enter. It does not tell you what dose to take.
Presets fill the reference vial size, water, and the low end of the dose range. They are editable starting points, not recommendations. U-100 means 100 units equals 1 mL. Change the water and every unit line changes with it. All figures are research reference math only.
| Vial size | BAC water | Dose | Draw (U-100) | Doses / vial |
|---|---|---|---|---|
| 2 mg | 2.0 mL | 100 mcg | 10 units | 20 |
| 2 mg | 2.0 mL | 200 mcg | 20 units | 10 |
| 5 mg | 2.0 mL | 250 mcg | 10 units | 20 |
| 5 mg | 2.0 mL | 500 mcg | 20 units | 10 |
| 10 mg | 2.0 mL | 500 mcg | 10 units | 20 |
| 10 mg | 2.0 mL | 1 mg (1000 mcg) | 20 units | 10 |
| 15 mg | 2.0 mL | 1.5 mg | 20 units | 10 |
| 20 mg | 2.0 mL | 1 mg (1000 mcg) | 10 units | 20 |
| 20 mg | 2.0 mL | 2 mg | 20 units | 10 |
Before you mix
The point of the gear list is not to sound technical. It is to remove avoidable errors. Most dosing confusion starts before a vial is ever mixed, because the wrong tool changes the handling, the pressure, and the accuracy of the whole setup.
A 29G insulin-style needle is a common default because it balances control against stopper wear. It is narrow enough to limit damage to the rubber vial top while still being practical for handling pressure. Thinner needles such as 31G can struggle to equalize pressure in some vial setups, which is a handling quirk, not a hard rule.
A 3mL syringe makes the water transfer easier to read and easier to control. It also stops you reaching for the same tiny dosing syringe to do both the mixing and the micro-dose math. The tool used to mix should not be the tool used to read small unit pulls.
Where you can, draw the full water amount once and finish the mix in one controlled entry. Fewer punctures means less stopper wear, less handling error, and a cleaner process. Repeated tiny entries just create more chances for pressure problems and contamination.
For a vial you will use more than once, bacteriostatic water is generally preferred because the benzyl alcohol (a mild preservative) helps limit bacterial growth over time. Sterile water is not the same thing. It can be fine for a single-use research context, but for repeated entry, BAC water is the cleaner practical choice.
The method
Lyophilized (freeze-dried) powder looks stable because it is dry. The moment water goes in, handling starts to matter. The standard handling concern is that blasting water straight onto the powder puck may disturb the peptide and cost a little potency. This is closer to careful-handling convention than settled data for most short peptides, and one fast push does not automatically ruin a vial. The cleaner method is simply the more rational one, so it is the one worth building as a habit.
Pull a little air in first so the vial does not fight the transfer. Pressure problems are what make people push too hard.
Angling it gives the water a glass wall to run down instead of dropping straight onto the powder.
Do not blast the puck. Let the liquid run down the side and settle gradually.
The right speed feels almost boring. A slow transfer lets the solution spread without turning into turbulence.
Skip hard shaking. A gentle swirl or slow roll dissolves the powder while keeping the structure intact.
The biggest math error in the category. If the water amount changes, every unit line changes. A correct vial amount with the wrong water still gives you the wrong syringe read.
For a single use they can sound interchangeable, but for a multi-use vial the contamination logic differs. The issue is not the word sterile. It is repeated entry over time.
Hard shaking is usually a sign the process got rushed. Gentle movement is the cleaner standard.
Most reconstituted peptides are treated as refrigerated materials. Leaving them out adds avoidable degradation and shortens useful life.
The syringe that reads 5, 10, or 20 unit pulls should not be the one transferring the full water volume. That is how small reading errors get baked in from the start.
After you mix
Keep reconstituted vials refrigerated, out of light, and handled as if every extra touch lowers quality. Clean stopper technique, fewer entries, and calm handling matter more than people think, because small mechanical errors add up over time.
Dry peptides are commonly stored frozen for months, sometimes longer, depending on the compound and handling quality. Once out of the freezer, keep temperature swings to a minimum before you mix.
Once wet, most research setups treat 14 to 28 days refrigerated as the conservative window for most peptides, with certain compounds discussed as shorter or more fragile exceptions. Always confirm per compound.
Concentration and preparation errors create fake protocol problems. Someone can misread a compound when the real issue was the mix, the syringe math, the storage, or the handling. That is why mechanics come first.
If a solution turns cloudy for no reason, shows visible particles, changes color unexpectedly, or has been handled carelessly enough that you no longer trust it is sterile, do not force an interpretation. Stop using that vial and reset the process.
Concentration and preparation errors create fake protocol problems. A researcher can blame a compound when the real problem was the mix, the syringe math, the storage, or the handling. Get the mechanics right first, then judge the compound.
Next step
This guide fixes preparation. It does not diagnose why a protocol stalled, why hunger changed, why energy dropped, or why a stack got harder to read. The Protocol Bottleneck Tool does. Answer a short set of questions about your current protocol and it maps your situation across seven bottleneck categories, then tells you where the friction most likely is and what to look at first. It takes about three minutes, it is free, and it does not ask what to dose or point you at a vendor.
